SKYE — Skye Bioscience, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1516551 ·
Last close
$1.00
Market Cap
$4.43M
52W High
$11.20
52W Low
$0.50
ADV30
90,972
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -4,973,683 | 69,126 | 5,072,591 | 4,815,851 | 3,712,182 |
| Jun 2026 | 0 | — | -7,811,303 | -10,786,594 | 11,033,795 | 8,068,357 | 11,531,102 |
| Mar 2026 | 0 | — | -12,674,366 | -12,509,361 | 19,416,736 | 8,149,015 | 10,404,932 |
| Dec 2025 | 0 | — | -14,895,544 | -14,441,963 | 28,313,633 | 5,882,498 | 8,289,458 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,810,453
Investing CF
$23,201,692
Financing CF
$-161,126
CapEx
$-6,312
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.16
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-210,170,441
Inventory
—
Receivables
$7,356
ST Investments
$1,995,784
EBIT TTM
$-50,483,680
Pretax Income TTM
$-50,489,178
Interest Exp TTM
$5,498
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -58,163,565 | -55,924,814 | 28,313,633 | 8,289,458 | 20,024,175 | -43,062,529 |
| Dec 2024 | 0 | -36,427,435 | -26,567,123 | 72,763,773 | 4,612,049 | 68,151,724 | -25,237,480 |
| Dec 2023 | 0 | -13,671,801 | -37,644,784 | 11,940,411 | 14,072,229 | -2,131,818 | -13,952,178 |
| Dec 2022 | 0 | -12,106,422 | -19,481,602 | 9,111,072 | 12,119,126 | -3,008,054 | -12,744,072 |
TTM Snapshot
Revenues TTM
$2,763,224
NetIncome TTM
$-50,492,578
OpCashFlow TTM
—
Assets (Latest)
$11,033,795
Forward EPS
$-6.67
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADXN | Addex Therapeutics Ltd. | $4.43M | $3.50 | — |
| TCRT | Alaunos Therapeutics, Inc. | $4.22M | $1.66 | — |
| LTRN | Lantern Pharma Inc. | $4.67M | $0.37 | — |
| KPRX | KIORA PHARMACEUTICALS INC | $4.11M | $0.93 | — |
| CNSY | CERENOME, INC. | $4.78M | $0.63 | — |
News headlines (Yahoo Finance, 1h cache)
Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Fibrex ...
2026-08-17 17:32 · Yahoo
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
2026-08-14 13:33 · Yahoo
The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea
2026-07-17 10:39 · Yahoo
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
2026-04-07 11:00 · Yahoo
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
2026-05-12 17:33 · Yahoo
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
2026-05-11 20:01 · Yahoo
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
2026-05-20 11:00 · Yahoo
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
2026-04-02 11:00 · Yahoo
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
2026-03-18 05:06 · Yahoo
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
2026-03-12 01:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.